Clinical trial
Ispinesib In Combination With Carboplatin In Patients With Solid Tumors
NCT00136578 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00136578 |
|---|---|
| Title | Ispinesib In Combination With Carboplatin In Patients With Solid Tumors |
| Official title | A Phase I, Open-Label, Dose-Escalation Study of the Safety and Tolerability of Ispinesib in Combination With Carboplatin on an Every 21-Day Schedule in Subjects With Advanced Solid Tumors. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Solid Tumours |
| Intervention type | Drug |
| Interventions | SB-715992, carboplatin |
| Enrollment | 30 |
| Start date | Oct 20, 2004 |
| Primary completion | Oct 25, 2006 |
| Completion | Oct 25, 2006 |
| First posted | Aug 29, 2005 |
| Last update posted | Sep 25, 2017 |
| Countries | United Kingdom, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: